An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure

https://doi.org/10.1016/j.taap.2016.04.013Get rights and content

Highlights

  • Ten P450 isoforms activities assessed simultaneously with only one incubation.

  • P450 activity levels measured using the metabolic ratio approach.

  • IC50 values generated 10-fold faster and cheaper compared to individual assays.

  • P450 2B6 was the most affected by pesticides with IC50 in the nanomolar range.

  • Cumulative inhibition of P450 2B6 by mixtures of four low-dosed insecticides.

Abstract

Acute exposure to environmental factors strongly affects the metabolic activity of cytochrome P450 (P450). As a consequence, the risk of interaction could be increased, modifying the clinical outcomes of a medication. Because toxic agents cannot be administered to humans for ethical reasons, in vitro approaches are therefore essential to evaluate their impact on P450 activities.

In this work, an extensive cocktail mixture was developed and validated for in vitro P450 inhibition studies using human liver microsomes (HLM). The cocktail comprised eleven P450-specific probe substrates to simultaneously assess the activities of the following isoforms: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2 and subfamily 3A. The high selectivity and sensitivity of the developed UHPLC-MS/MS method were critical for the success of this methodology, whose main advantages are: (i) the use of eleven probe substrates with minimized interactions, (ii) a low HLM concentration, (iii) fast incubation (5 min) and (iv) the use of metabolic ratios as microsomal P450 activities markers. This cocktail approach was successfully validated by comparing the obtained IC50 values for model inhibitors with those generated with the conventional single probe methods. Accordingly, reliable inhibition values could be generated 10-fold faster using a 10-fold smaller amount of HLM compared to individual assays. This approach was applied to assess the P450 inhibition potential of widespread insecticides, namely, chlorpyrifos, fenitrothion, methylparathion and profenofos. In all cases, P450 2B6 was the most affected with IC50 values in the nanomolar range. For the first time, mixtures of these four insecticides incubated at low concentrations showed a cumulative inhibitory in vitro effect on P450 2B6.

Introduction

Cytochromes P450 (P450) are the major phase I metabolic enzymes involved in the oxidative biotransformation of xenobiotics as well endogenous compounds. High inter-individual differences in P450 activities have been described in many publications, and major sources of this variability are associated with genetic features (e.g., gene expression regulation, polymorphism, gender, and age), environmental influences (e.g., stress, diet, and life style) and/or xenobiotic exposure (e.g., drug therapy, dietary supplements, environmental pollutants, and toxic substances). As a consequence, the perturbations of their activities (inhibition/reduction or increase/induction) may lead to a significant variation in the concentration of a xenobiotic and its metabolites at the target site, i.e., enhanced clearance, production of toxic metabolites or toxic accumulation of the parent compound. The inhibition of P450 has been shown to produce unexpected severe effects in drug pharmacokinetics and clinical responses, particularly due to drug-drug interactions (DDIs) (Zanger and Schwab, 2013).

The evaluation of the P450 interaction potential of a xenobiotic must thus be conducted to predict the risks in the case of co-exposure. DDI investigations in the early discovery process have already been achieved to reduce the frequency of costly late failures of the drug candidates and to promote safer medical treatment. In contrast to the clinical environment, where DDIs could also be investigated in vivo thanks to dedicated clinical studies, drug-toxicant interactions cannot be easily performed for evident ethical reasons. However, because toxicants are ubiquitous in the environment and humans are chronically and/or acutely exposed throughout their entire lives, their impact on P450 activities should be more thoroughly investigated, even if official recommendations in this context are not yet enforced (Pelkonen et al., 2008).

According to the 3Rs principle (Replace, Reduce and Refine) for promoting a more reasonable and ethical animal testing, in vitro approaches have been further recommended to evaluate and/or anticipate the impact of toxicants on P450 activities. Hepatocytes are currently the gold standard in vitro tool for performing P450 induction studies, whereas for studying the inhibition phenomenon at the enzyme level, human liver microsomes (HLM) can be judiciously employed as an in vitro native phase I enzyme source thanks to their commercial availability, ease of handling and reliable in vivo extrapolation (Parkinson et al., 2010).

Nowadays, except for numerous academic settings, in vitro P450 inhibition assays are generally conducted using higher-end robotic systems or high-throughput-MS methods (e.g., RapidFire® and Phytronix®), which drastically increase the efficiency of the assays (Haarhoff et al., 2016, Wu et al., 2007, Wu et al., 2012). Alternatively, the cocktail approach has been developed to efficiently and rapidly monitor the activities of several microsomal P450 isoforms within a single test, reducing the time and assay costs when expensive robotic handling instruments are not available (Lahoz et al., 2008). However, when an extended substrate mixture is used for an overall P450 inhibition screening, the following numerous challenges have been identified: (i) an enhanced risk of probe-probe interactions, (ii) a more difficult implementation according to the different optimal incubation conditions for both rapid-and slow-turnover substrates and (iii) the need for efficient separation-based analytical techniques such as LC/MS methods for the reliable analysis of the high number of analytes. Above all, the combination of high-turnover substrates together with low-turnover substrates has often been recognized as the major issue for implementing unique optimal incubation conditions. Indeed, to allow the detection of low amounts of a metabolite, a relatively high concentration of a slow-turnover substrate along with a high protein concentration and incubation time have to be employed. This practice indirectly promoted the occurrence of probe-probe interactions and simultaneously created disadvantaged conditions for high-turnover substrates. Due to the presence of probe interactions not fully characterized as well as sub-optimal assay conditions for each substrate, the reliability of inhibition investigations could be reduced (Spaggiari et al., 2014a). Recently, the separation of critical substrates into two distinct cocktails has been successfully proposed to overcome probe interactions and facilitate cocktail design. Authors also highlighted the importance of chromatographically separating metabolites and substrates still present in the incubation mixture prior to analysis to avoid potential and relevant analytical interferences due to co-elution, which could not be adjusted using a single analytical standard. Besides pooled samples could be analyzed to save analysis time, this methodology duplicated reagent consumption and manipulations (Dinger et al., 2014a). Alternatively, with the powerful separation capabilities of ultra-high-pressure liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), including its high sensitivity, selectivity and resolution, it was possible to overcome some of the difficulties of cocktail approach. Analytical interferences were corrected using stable isotope-labeled metabolites to correct potential co-elutions (Kozakai et al., 2012).

In this study, an alternative analytical strategy was developed for the original design of an extensive cocktail assay for a microsomal P450 direct reversible inhibition screening (IC50 assay) for the most important isoforms involved in the biotransformations of clinically used drugs, namely, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2 and subfamily 3A. An optimized UHPLC separation of the eleven substrates and their P450-specific metabolites was combined with highly sensitive MS/MS detection to achieve favorable analytical and metabolic conditions for optimal cocktail incubation. As a novel aspect, P450 microsomal activities were expressed by combining metabolite formation with substrate depletion (i.e., metabolic ratio) rather than metabolite formation only in the analysis. Afterwards, the inhibition curves and subsequent IC50 values were compared to those obtained with the single probe approach. Finally, this assay demonstrated to be a promising safety assessment tool for the evaluation of environment-related direct reversible inhibition of P450 (e.g., pesticides, cosmetics, food additives, phytochemicals, diet, etc.), which is currently not systematically addressed in the panel of toxicological screening tests.

Section snippets

Chemicals, reagents, test compounds and other materials

Acetonitrile (MeCN), methanol (MeOH) and water of ULC/MS grade were purchased from Biosolve (Valkenswaard, Netherlands). Formic acid was obtained from Merck (Darmstadt, Germany). (S)-(+)-N-3-benzylnirvanol (98%), chlorzoxazone (98%), O-desmethylastemizole (98%) hydroxybupropion (95%), 6-hydroxychlorzoxazone (97%), 5-hydroxyomeprazole (98%) and omeprazole (98%) were purchased from Toronto Research Chemicals (Ontario, Canada). Acetaminophen (99%), ammonium hydroxide, amodiaquine dihydrochloride

Cocktail composition and analytical method development

For the first time in the context of the cocktail approach, eleven P450 probe substrates, namely, phenacetin (1A2), coumarin (2A6), bupropion (2B6), amodiaquine (2C8), diclofenac (2C9), omeprazole (2C19), dextromethorphan (2D6), chlorzoxazone (2E1), astemizole (2J2), midazolam and testosterone (3A subfamily), have been selected for simultaneously monitoring the most clinically and toxicologically relevant P450 isoforms in HLM. According to our recent survey of the published in vitro cocktails,

Conclusion

The presented cocktail approach included, for the first time, eleven probe substrates for direct reversible inhibition screening of xenobiotics affecting the ten most relevant P450 isoforms in human metabolism. Thanks to the high analytical sensitivity, it was possible to minimize probe-probe interactions in the cocktail and drastically reduce both the incubation time and reagent consumption. The IC50 values obtained were in agreement with reference values obtained by the single probe methods.

Abbreviations

DDIdrug-drug interactions
DTdwell time
ESIelectrospray ionization
HEPES4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
pHLMpooled human liver microsomes
LLOQlower limit of quantification
MeCNacetonitrile
MeOHmethanol
Me2SOdimethyl sulfoxide
NADPHβ-nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt
NOECno observed effect concentration
OPorganophosphorothionate
P450cytochrome P450
PBBKphysiologically-based biokinetics
QqQ/MStriple-quadrupole mass spectrometer
S/Nsignal-to-noise

Funding sources

No funding sources.

Transparency document

Transparency document.

Acknowledgments

The authors wish to thank Dr. Szabolcs Fekete for his valuable help regarding the Drylab®2010 Plus modeling software.

References (61)

  • K. Kozakai et al.

    Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards

    Drug Metab. Pharmacokinet.

    (2012)
  • E. Mutch et al.

    Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver

    Toxicology

    (2006)
  • A. Parkinson et al.

    System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes

    Drug Metab. Pharmacokinet.

    (2010)
  • M. Rodriguez-Aller et al.

    Coupling ultra high-pressure liquid chromatography with mass spectrometry: constraints and possible applications

    J. Chromatogr. A

    (2013)
  • C. Sams et al.

    Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes

    Toxicol. Lett.

    (2000)
  • D. Spaggiari et al.

    Coupling ultra-high-pressure liquid chromatography with mass spectrometry for in-vitro drug-metabolism studies

    Trends Analyt. Chem.

    (2014)
  • D. Spaggiari et al.

    A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies

    J. Pharmaceut. Biomed.

    (2014)
  • D. Spaggiari et al.

    Comparison of liquid chromatography and supercritical fluid chromatography coupled to compact single quadrupole mass spectrometer for targeted in vitro metabolism assay

    J. Chromatogr. A.

    (2014)
  • D. Spaggiari et al.

    Contribution of various types of liquid chromatography-mass spectrometry instruments to band broadening in fast analysis

    J. Chromatogr. A

    (2013)
  • M. Turpeinen et al.

    Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay

    Eur. J. Pharm. Sci.

    (2005)
  • X. Wu et al.

    In vitro ADME profiling using high-throughput RAPIDFIRE mass spectrometry: cytochrome P450 inhibition and metabolic stability assays

    J. Biomol. Screen.

    (2012)
  • U.M. Zanger et al.

    Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

    Pharmacol. Ther.

    (2013)
  • K. Abass et al.

    The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches

    Toxicol. In Vitro

    (2012)
  • K. Abass et al.

    An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes

    J. Environ. Sci. Health B

    (2009)
  • H.Z. Bu et al.

    High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1

    Rapid Commun. Mass Spectrom.

    (2001)
  • A.O. Caggiano et al.

    In vitro evaluation of the effects of 4-aminopyridine on cytochrome P450 enzymes

    J. Drug Assess.

    (2013)
  • X. Cai et al.

    Validation of (−)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes

    Drug Metab. Dispos.

    (2004)
  • N. Cedergreen

    Quantifying synergy: a systematic review of mixture toxicity studies within environmental toxicology

    PLoS One

    (2014)
  • Y. Cheng et al.

    Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

    Biochem. Pharmacol.

    (1973)
  • J.M. Diamond et al.

    Evaluation of the test of significant toxicity for determining the toxicity of effluents and ambient water samples

    Environ. Toxicol. Chem.

    (2013)
  • Cited by (0)

    View full text